THYROID: Edited by Angela M. LeungLong noncoding RNAs in thyroid cancerSedaghati, Mahsa; Kebebew, Electron Author Information Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, California, USA Correspondence to Electron Kebebew, MD, Department of Surgery and Stanford Cancer Institute, Stanford University, 300 Pasteur Drive, H3642, Stanford, CA 94305, USA. Tel: +1 650 725 7830; e-mail: [email protected] Current Opinion in Endocrinology & Diabetes and Obesity 26(5):p 275-281, October 2019. | DOI: 10.1097/MED.0000000000000497 Buy Metrics Abstract Purpose of review Our understanding of the molecular pathology events involved in thyroid cancer initiation and progression and its subtypes has markedly improved as a result of multiomic studies. Recently, long noncoding RNA (lncRNA) have been shown to have a role in cancer initiation and progression and have also been studied in thyroid cancer. Recent findings lncRNA are dysregulated in thyroid cancer. lncRNA have tumor suppressive and oncogenic function in thyroid cancer cells and play a role in some of the established genetic drivers of thyroid cancer initiation and progression. Lastly, some lncRNA are associated with clinicopathologic features of thyroid cancer and circulating blood lncRNA could potentially detect the presence of thyroid cancer. Summary We highlight the possible clinical utility of analyzing lncRNAs as biomarkers for thyroid cancer diagnosis and prognosis and their association with common genetic changes associated with thyroid cancer. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.